2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

J Steffel, R Collins, M Antz, P Cornu, L Desteghe… - Ep …, 2021 - academic.oup.com
1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …

2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the …

RA Byrne, X Rossello, JJ Coughlan… - … Heart Journal: Acute …, 2024 - academic.oup.com
2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …

Microaxial flow pump or standard care in infarct-related cardiogenic shock

JE Møller, T Engstrøm, LO Jensen… - … England Journal of …, 2024 - Mass Medical Soc
Background The effects of temporary mechanical circulatory support with a microaxial flow
pump on mortality among patients with ST-segment elevation myocardial infarction (STEMI) …

Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial

Y Wang, S Li, Y Pan, H Li, MW Parsons, BCV Campbell… - The Lancet, 2023 - thelancet.com
Background There is increasing interest in replacing alteplase with tenecteplase as the
preferred thrombolytic treatment for patients with acute ischaemic stroke. We aimed to …

Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research

VARC-3 Writing Committee, P Généreux… - European heart …, 2021 - academic.oup.com
Abstract Aims The Valve Academic Research Consortium (VARC), founded in 2010, was
intended to (i) identify appropriate clinical endpoints and (ii) standardize definitions of these …

[HTML][HTML] Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA

Y Wang, X Meng, A Wang, X **e, Y Pan… - … England Journal of …, 2021 - Mass Medical Soc
Background Comparisons between ticagrelor and clopidogrel for the secondary prevention
of stroke in CYP2C19 loss-of-function carriers have not been extensively performed …

[HTML][HTML] Dual antiplatelet treatment up to 72 hours after ischemic stroke

Y Gao, W Chen, Y Pan, J **g, C Wang… - … England Journal of …, 2023 - Mass Medical Soc
Background Dual antiplatelet treatment has been shown to lower the risk of recurrent stroke
as compared with aspirin alone when treatment is initiated early (≤ 24 hours) after an acute …

Tissue plasminogen activator (tPA) treatment for COVID‐19 associated acute respiratory distress syndrome (ARDS): a case series

J Wang, N Hajizadeh, EE Moore… - … of thrombosis and …, 2020 - Wiley Online Library
A prothrombotic coagulopathy is commonly found in critically ill COVID‐19 patients with
acute respiratory distress syndrome (ARDS). A unique feature of COVID‐19 respiratory …

Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving …

H Watanabe, T Domei, T Morimoto, M Natsuaki… - Jama, 2019 - jamanetwork.com
Importance Very short mandatory dual antiplatelet therapy (DAPT) after percutaneous
coronary intervention (PCI) with a drug-eluting stent may be an attractive option. Objective …

Tirofiban for stroke without large or medium-sized vessel occlusion

W Zi, J Song, W Kong, J Huang, C Guo… - … England Journal of …, 2023 - Mass Medical Soc
Background The effects of the glycoprotein IIb/IIIa receptor inhibitor tirofiban in patients with
acute ischemic stroke but who have no evidence of complete occlusion of large or medium …